

LUD 5466.4 CIP - JEL/NDH

Further, claim 89 was presented previously. It was before the examiner when she issued the Advisory Action of June 20. Why wasn't it raised at that time? The claim language didn't change.


Finally, it is noted that the claim requires that the peptide bind to an MHC-Class II DR53 molecule. How open ended could this be?

This is the last response to an advisory action applicants will make. If the examiner sets forth any further advisory actions, a petition will be filed.

Allowance of this application is in order.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.


Norman D. Hanson, Esq.
Registration No. 30,946

666 Fifth Avenue
New York, New York 10103-3198
Telephone: 212-318-3168
Telecopier: 212-318-3400